RIPK1-IN-32

RIPK1-IN-32 is a RIPK inhibitor with anti-inflammatory activity. RIPK1-IN-32 inhibits nitric oxide (NO) release with an IC50 of 3.26 μM. RIPK1-IN-32 significantly alleviates acute liver injury associated with sepsis through the RIPK1/NF-κB/MAPK pathway, therefore preventing the nuclear translocation of p65 and c-fos, which results in reduced expression of TNF-α and IL-6. RIPK1-IN-32 can be used for the study of acute liver injury and sepsis[1].

Product Specifications

UNSPSC

12352211

Target

Interleukin Related; NF-κB; p38 MAPK; RIP kinase; TNF Receptor

Related Pathways

Apoptosis; Immunology/Inflammation; MAPK/ERK Pathway; NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Infection; Inflammation/Immunology

Smiles

[H][C@@]12CC[C@@]([C@]3(C)[C@@](C4=C(C(O[C@H]4C3)=O)CC/C=C(C)/C)([H])C[C@H]5O)(C)[C@@]5([C@]1(CC[C@H]([C@H]2C)OC(CCSSCCC(NOCC6=CC=CC=C6)=O)=O)C)[H]

Molecular Formula

C42H59NO7S2

Molecular Weight

754.05

References & Citations

[1]Gao J, et al. Discovery of novel fusidic acid derivatives in mitigating LPS-induced acute liver injury by modulating RIPK1. Bioorg Med Chem Lett. 2025 Jul 1;128:130322.